VG Life Sciences, a leader in devising safe and effective therapies in a variety of infectious and inflammatory diseases, has announced that the Phase I study of the promising anti-cancer drug Pre-IND yielded positive results in stage 2 clinical trials. These clinical trials were conducted at Research Center of The University of Texas Health Science Center in San Antonio.
http://bionews-tx.com/news/2013/04/04/vg-life-sciences-reports-positive-safety-results-from-second-cohort-enrollment-in-solid-tumor-clinical-trial-at-ut-health-science-center/
No comments:
Post a Comment